Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + anti-angiogenic therapy + gemcitabine/cisplatin for advanced biliary tract tumors (single-arm, first-line)
ChiCTR2600124193Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in biliary cancer, intrahepatic cholangiocarcinoma (ICC), cholangiocarcinoma (CCA) and 1 more, sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival. Started May 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600124193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124193.